Q-GESIC
Clinical safety rating
cautionComprehensive clinical and safety monograph for Q-GESIC (Q-GESIC).
Q-GESIC is a centrally acting non-opioid analgesic; its exact mechanism is unknown but may involve inhibition of cyclooxygenase (COX) and modulation of descending serotonergic and noradrenergic pathways.
| Metabolism | Hepatic via CYP450 (CYP1A2 and CYP2D6) and glucuronidation. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; <5% metabolized via CYP enzymes. |
| Half-life | Terminal elimination half-life is 2-4 hours; clinical context: requires dosing every 4-6 hours for sustained analgesia. |
| Protein binding | Approximately 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 2-3 L/kg; indicates extensive tissue distribution with accumulation in inflamed tissues. |
| Bioavailability | Oral: 70-80% due to first-pass metabolism; Intramuscular: 90-100%; Intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes; Intramuscular: 10-20 minutes. |
| Duration of Action | Analgesic effect lasts 4-6 hours after oral or intramuscular administration; intravenous duration is shorter at 2-3 hours. |
| Molecular Weight | 230.26 |
1-2 tablets (325-650 mg acetaminophen and 5-10 mg hydrocodone) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: Administer every 6 hours; maximum 5 tablets daily. GFR 10-29 mL/min: Administer every 8 hours; maximum 4 tablets daily. GFR <10 mL/min: Not recommended. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and extend interval to every 8 hours; maximum 4 tablets daily. Child-Pugh Class C: Avoid use. |
| Pediatric use | Weight-based dosing for hydrocodone: 0.1-0.2 mg/kg/dose every 4-6 hours as needed; maximum 6 doses per day. For acetaminophen: 10-15 mg/kg/dose every 4-6 hours; maximum 75 mg/kg/day. Not recommended in children <2 years. |
| Geriatric use | Initiate with lowest dose (1 tablet every 6 hours) and titrate cautiously due to increased risk of respiratory depression, falls, and acetaminophen hepatotoxicity. Maximum 6 tablets daily. Avoid in frail elderly. |
| 1st trimester | Avoid during first trimester; limited data but potential risk of cardiovascular malformations with NSAIDs use. |
| 2nd trimester | Use only if clearly needed; risk of premature closure of ductus arteriosus and oligohydramnios increases after 20 weeks gestation. |
| 3rd trimester | Contraindicated in third trimester (after 20 weeks) due to risk of premature closure of ductus arteriosus, oligohydramnios, and fetal renal impairment. |
Clinical note
Comprehensive clinical and safety monograph for Q-GESIC (Q-GESIC).
| Placental transfer | Q-GESIC crosses the placenta; fetal serum concentrations are approximately 10-20% of maternal levels. Transfer increases with gestational age and is higher in the third trimester. |
| Breastfeeding | Q-GESIC is excreted into breast milk in small amounts. Concentrations are low and unlikely to cause adverse effects in infants. However, due to potential risks of NSAIDs in neonates (e.g., platelet dysfunction, renal impairment), caution is advised, especially in premature infants or those with compromised renal function. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Limited human data; animal studies suggest skeletal abnormalities at high doses. Second/Third trimesters: Risk of premature ductus arteriosus closure and oligohydramnios with NSAID use; avoid after 30 weeks gestation. |
| Fetal Monitoring | Monitor amniotic fluid index if used beyond 20 weeks; fetal echocardiography if used after 30 weeks for ductus arteriosus patency. Maternal renal function and bleeding time assessment. |
| Fertility Effects | Reversible inhibition of ovulation; may delay time to pregnancy. No evidence of permanent infertility. |
■ FDA Black Box Warning
None.
| Serious Effects |
History of hypersensitivity to Q-GESIC or any NSAIDActive peptic ulcer disease or gastrointestinal bleedingSevere heart failure (NYHA class III-IV)Third trimester pregnancy (after 20 weeks)Significant renal impairment (eGFR <30 mL/min/1.73m²)History of asthma, urticaria, or allergic reactions after taking aspirin or other NSAIDs
| Precautions | Hepatotoxicity with overdose or chronic use; severe skin reactions (SJS/TEN); hypersensitivity reactions; avoid with severe hepatic impairment. |
| Food/Dietary | Avoid alcohol and grapefruit juice (may increase sedation or affect drug levels). Take with food if gastrointestinal upset occurs. |
| Clinical Pearls | Q-GESIC (qgesic) is a fixed-dose combination of guaifenesin 200 mg and diphenhydramine 12.5 mg. Advise patients to swallow tablets whole; crushing may cause throat irritation. Caution in elderly due to anticholinergic effects (confusion, urinary retention). Monitor for sedation; avoid concurrent CNS depressants. Use with caution in asthma (diphenhydramine may thicken secretions). |
| Patient Advice | Take this medication exactly as directed; do not crush or chew tablets. · Avoid driving or operating heavy machinery until you know how this medication affects you. · Do not use with other products containing diphenhydramine or other antihistamines. · Drink plenty of fluids to help loosen mucus. · Consult a doctor if symptoms persist for more than 7 days or are accompanied by fever. |
Loading safety data…